Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Rosenberg

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
The American Journal of Clinical Nutrition|February 5, 2010
Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiencyPaul Lips, Neil Binkley, Michael Pfeifer, et al.
Cell Cycle (Georgetown, Tex.)|January 26, 2011
ATM-dependent ERK signaling via AKT in response to DNA double-strand breaksAshraf Khalil, Rhiannon N Morgan, Bret R Adams, et al.
Calcified Tissue International|April 12, 2011
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiencyStuart H Ralston, Neil Binkley, Steven Boonen, et al.
Bone|March 3, 2007
A cross-sectional study of bone turnover markers in healthy premenopausal womenAnne E de Papp, Henry G Bone, Michael P Caulfield, et al.
Cytokine|February 10, 2015
The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjectsNina Hastrup, Sauzanne Khalilieh, David C Dale, et al.
Health Promotion Practice|January 22, 2020
An Approach to Adapting a Community-Based Cancer Control Intervention to Organizational ContextCheryl L Knott, Janice Bowie, C Daniel Mullins, et al.
Investigational New Drugs|March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen, Robert DiPaola, Glenn Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|August 29, 2014
A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosisJohan Halse, Susan Greenspan, Felicia Cosman, et al.
Calcified Tissue International|August 6, 2013
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosisChristian Roux, Neil Binkley, Steven Boonen, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Clinical Lipidology|February 5, 2011
Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive proteinMichael H Davidson, Nicola Abate, Christie M Ballantyne, et al.
The American Journal of Clinical Nutrition|February 5, 2010
Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiencyPaul Lips, Neil Binkley, Michael Pfeifer, et al.
Cell Cycle (Georgetown, Tex.)|January 26, 2011
ATM-dependent ERK signaling via AKT in response to DNA double-strand breaksAshraf Khalil, Rhiannon N Morgan, Bret R Adams, et al.
Calcified Tissue International|April 12, 2011
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiencyStuart H Ralston, Neil Binkley, Steven Boonen, et al.
Bone|March 3, 2007
A cross-sectional study of bone turnover markers in healthy premenopausal womenAnne E de Papp, Henry G Bone, Michael P Caulfield, et al.
Cytokine|February 10, 2015
The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjectsNina Hastrup, Sauzanne Khalilieh, David C Dale, et al.
Health Promotion Practice|January 22, 2020
An Approach to Adapting a Community-Based Cancer Control Intervention to Organizational ContextCheryl L Knott, Janice Bowie, C Daniel Mullins, et al.
Investigational New Drugs|March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen, Robert DiPaola, Glenn Liu, et al.
The Journal of Clinical Endocrinology and Metabolism|August 29, 2014
A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosisJohan Halse, Susan Greenspan, Felicia Cosman, et al.
Calcified Tissue International|August 6, 2013
Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosisChristian Roux, Neil Binkley, Steven Boonen, et al.
Pageof 5